Quick Answer
Annovis Bio, Inc. reported Research And Development Expense of $25.22 million for the year ending 2025.
- Annovis Bio, Inc. showed an increase of +26.1% in Research And Development Expense from 2024 to 2025.
- This data is from Annovis Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $6.0 thousand | Q2 2019: $6.0 thousand | Q3 2019: $2.0 thousand | Q1 2020: $66.4 thousand | Q2 2020: $856.5 thousand | Q3 2020: $718.9 thousand | Q1 2021: $2.39 million | Q2 2021: $1.82 million | Q3 2021: $1.38 million | Q1 2022: $2.15 million | Q2 2022: $4.03 million | Q3 2022: $4.12 million | Q1 2023: $7.79 million | Q2 2023: $8.26 million | Q3 2023: $13.84 million | Q1 2024: $6.51 million | Q2 2024: $5.79 million | Q3 2024: $2.69 million | Q1 2025: $5.01 million | Q2 2025: $5.16 million | Q3 2025: $6.29 million.
- Over the full 7 years of available data (2019 to 2025), Annovis Bio, Inc.'s Research And Development Expense has grown by 3,148.4%.
- Historical annual values: Fiscal year 2025: $25.22 million | Fiscal year 2024: $20.00 million | Fiscal year 2023: $38.79 million | Fiscal year 2022: $16.52 million | Fiscal year 2021: $8.48 million | Fiscal year 2020: $3.05 million | Fiscal year 2019: $776.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: